Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 30;15(13):3454.
doi: 10.3390/cancers15133454.

Dose-Volume Histogram Parameters and Quality of Life in Patients with Prostate Cancer Treated with Surgery and High-Dose Volumetric-Intensity-Modulated Arc Therapy to the Prostate Bed

Affiliations

Dose-Volume Histogram Parameters and Quality of Life in Patients with Prostate Cancer Treated with Surgery and High-Dose Volumetric-Intensity-Modulated Arc Therapy to the Prostate Bed

Luca Hanke et al. Cancers (Basel). .

Abstract

Introduction: Prostate bed radiotherapy (RT) is a major affecter of patients' long-term quality of life (QoL). To ensure the best possible outcome of these patients, dose constraints are key for optimal RT planning and delivery. However, establishing refined dose constraints requires access to patient-level data. Therefore, we aimed to provide such data on the relationship between OAR and gastrointestinal (GI) as well as genitourinary (GU) QoL outcomes of a homogenous patient cohort who received dose-intensified post-operative RT to the prostate bed. Furthermore, we aimed to conduct an exploratory analysis of the resulting data.

Methods: Patients who were treated with prostate bed RT between 2010 and 2020 were inquired about their QoL based on the Expanded Prostate Cancer Index Composite (EPIC). Those (n = 99) who received volumetric arc therapy (VMAT) of at least 70 Gy to the prostate bed were included. Dose-volume histogram (DVH) parameters were gathered and correlated with the EPIC scores.

Results: The median age at the time of prostate bed RT was 68.9 years, and patients were inquired about their QoL in the median 2.3 years after RT. The median pre-RT prostate-specific antigen (PSA) serum level was 0.35 ng/mL. The median duration between surgery and RT was 1.5 years. The median prescribed dose to the prostate bed was 72 Gy. A total of 61.6% received prostate bed RT only. For the bladder, the highest level of statistical correlation (p < 0.01) was seen for V10-20Gy, Dmean and Dmedian with urinary QoL. For bladder wall, the highest level of statistically significant correlation (p < 0.01) was seen for V5-25Gy, Dmean and Dmedian with urinary QoL. Penile bulb V70Gy was statistically significantly correlated with sexual QoL (p < 0.05). A larger rectal volume was significantly correlated with improved bowel QoL (p < 0.05). Sigmoid and urethral DVH parameters as well as the surgical approach were not statistically significantly correlated with QoL.

Conclusion: Specific dose constraints for bladder volumes receiving low doses seem desirable for the further optimization of prostate bed RT. This may be particularly relevant in the context of the aspiration of establishing focal RT of prostate cancer and its local recurrences. Our comprehensive dataset may aid future researchers in achieving these goals.

Keywords: dose constraints; dose-volume histogram; prostate bed; prostate cancer; quality of life; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

P.W. has a patent application titled ‘Method for detection of neurological abnormalities’ outside of the submitted work. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Inclusion workflow. Abbreviations: IC—informed consent, RT—radiation therapy, VMAT—volumetric intensity-modulated arc therapy.
Figure 2
Figure 2
Histograms to illustrate the distributions of selected patient characteristics.
Figure 3
Figure 3
Association between bladder dose and urine-related quality of life. Positive correlation coefficients indicate a positive correlation, negative coefficients indicate a negative correlation and 0 indicates no correlation. The significance level of the correlation coefficients is indicated by asterisks (* denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001).
Figure 4
Figure 4
Association between bladder wall dose and urine-related quality of life. Positive correlation coefficients indicate a positive correlation, negative coefficients indicate a negative correlation and 0 indicates no correlation. The significance level of the correlation coefficients is indicated by asterisks (* denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001).
Figure 5
Figure 5
Scatterplots of the median bladder dose [Gy] and different quality of life domains (urinary summary, urinary function, urinary bother, urinary incontinence and urinary irritative/obstructive symptoms). The line indicates the fit of a linear regression model, while translucent bands indicate the 95% confidence interval. While there was a significant correlation between the median bladder dose with urinary summary, urinary function, urinary bother and urinary incontinence, the correlation between the median bladder dose and irritative/obstructive symptoms did not reach significance.
Figure 6
Figure 6
Association between surgical approach and quality of life. Positive correlation coefficients indicate a positive correlation, negative coefficients indicate a negative correlation and 0 indicates no correlation. The significance level of the correlation coefficients is indicated by asterisks (*** denotes p < 0.001).

Similar articles

Cited by

References

    1. Emami B., Lyman J., Brown A., Cola L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., Wesson M. Tolerance of Normal Tissue to Therapeutic Irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:109–122. doi: 10.1016/0360-3016(91)90171-Y. - DOI - PubMed
    1. Bentzen S.M., Constine L.S., Deasy J.O., Eisbruch A., Jackson A., Marks L.B., Ten Haken R.K., Yorke E.D. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:S3–S9. doi: 10.1016/j.ijrobp.2009.09.040. - DOI - PMC - PubMed
    1. Olsson C.E., Jackson A., Deasy J.O., Thor M. A Systematic Post-QUANTEC Review of Tolerance Doses for Late Toxicity after Prostate Cancer Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2018;102:1514–1532. doi: 10.1016/j.ijrobp.2018.08.015. - DOI - PMC - PubMed
    1. Petersen P.M., Cook A.D., Sydes M.R., Clarke N., Cross W., Kynaston H., Logue J., Neville P., Payne H., Parmar M.K., et al. Salvage Radiation Therapy after Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial. Int. J. Radiat. Oncol. Biol. Phys. 2023 doi: 10.1016/j.ijrobp.2023.04.032. - DOI - PMC - PubMed
    1. Kneebone A., Fraser-Browne C., Duchesne G.M., Fisher R., Frydenberg M., Herschtal A., Williams S.G., Brown C., Delprado W., Haworth A., et al. Adjuvant Radiotherapy versus Early Salvage Radiotherapy Following Radical Prostatectomy (TROG 08.03/ANZUP RAVES): A Randomised, Controlled, Phase 3, Non-Inferiority Trial. Lancet Oncol. 2020;21:1331–1340. doi: 10.1016/S1470-2045(20)30456-3. - DOI - PubMed